Blue­bird bio com­pletes split in­to two com­pa­nies; BeiGene builds out Brukin­sa da­ta at ASH

Blue­bird bio has been of­fi­cial­ly split in half.

Both sides of the once-sin­gu­lar cell and gene ther­a­py com­pa­ny an­nounced Thurs­day they have com­plet­ed their split in­to two biotechs: A gene ther­a­py-fo­cused out­fit that will re­tain the old avian name and a new on­col­o­gy-fo­cused firm that will go by 2sev­en­ty bio.

The move, ex­ec­u­tives say, will al­low each com­pa­ny to fo­cus on bring­ing ther­a­pies to mar­ket in fields that re­quire very dif­fer­ent types of ex­per­tise.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.